Access Bio has signed an agreement with Partnership for Supply Chain Management (PFSCM) to supply the company’s malaria rapid diagnostics test (RDT) kit to Chemonics International and Médicins Sans Frontières (Doctors Without Borders).
PFSCM is a U.S. nonprofit organization providing global procurement and distribution services to low- and middle-income countries.
Under the accord, Access Bio will supply 3.3 billion won ($2.8 million) worth of malaria RDT kits.
With the agreement, the company believes that they have secured a leading position in the malaria RDT market as it has also recently received a 2.9 billion won order from PFSCM after receiving additional purchase requests from customers.
“We expect the sales recovery of Malaria RDT to continue, as we have continuously secured a stable order backlog in the second half of the year,” a company official said. “Also, as the flu season begins, we are strengthening sales of flu diagnostic products through our subsidiary Wells Bio and are doing our best to expand sales of new products such as HIV and Dengue RDT.”
With such strong sales, the company has consolidated sales of 22 billion won in the first half of this year, a drastic 101 percent increase from the same period last year.
<© Korea Biomedical Review, All rights reserved.>